Faculty Profiles - Tanioka Maki

Papers - Tanioka Maki

Division display 1 - 20 of about 74 ／ All the affair displays >>

Definitions of, Advances in, and Treatment Strategies for Breast Cancer Oligometastasis

Tadahiko Shien, Shogo Nakamoto, Yuki Fujiwara, Maya Kosaka, Yuki Narahara, Kento Fujii, Reina Maeda, Shutaro Kato, Asuka Mimata, Ryo Yoshioka, Chihiro Kuwahara, Takahiro Tsukioki, Yuko Takahashi, Tsuguo Iwatani, Maki Tanioka

Cancers 2025.7

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

A. Fernandez-Martinez, M. Tanioka, S.G. Ahn, P. Zagami, T. Pascual, M. Rediti, G. Tang, K.A. Hoadley, D. Venet, N.U. Rashid, P.A. Spears, S. Di Cosimo, E. de Azambuja, A. Choudhury, P. Rastogi, M.N. Islam, J. Cortes, A. Llombart-Cussac, S.M. Swain, C. Sotiriou, A. Prat, C.M. Perou, L.A. Carey

Annals of Oncology 2025.4

Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness. International journal

Tomoka Mamori, Maki Tanioka, Kenji Takada, Hirofumi Hamano, Takahiro Tsukioki, Yuko Takahashi, Tsuguo Iwatani, Tadahiko Shien, Shinichi Toyooka

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2024.10

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Despite the global use of trastuzumab biosimilars, concerns remain regarding their efficacy and safety. In particular, when used concurrently with pertuzumab, trastuzumab biosimilars lack extensive real-world data and safety information. Additionally, as cancer drug expenditures continue to rise worldwide, cost savings from biosimilars have become increasingly important. OBJECTIVE: This study aims to assess the safety, efficacy, and cost effectiveness of trastuzumab originators and their biosimilars in real-world clinical settings, focusing on a large patient population. METHODS: The analysis included 31,661 patients with HER2-positive breast cancer from the Medical Data Vision Co., Ltd. database in Japan. Additionally, adverse event reports for the trastuzumab originator and its biosimilars were obtained for 58,799 patients from the World Health Organization's VigiBase, the global adverse event reporting database. RESULTS: No significant differences were observed in heart failure hospitalizations, liver dysfunction, or infusion reaction rates in both the Medical Data Vision Co., Ltd. database and the World Health Organization's VigiBase. In the Medical Data Vision Co., Ltd. database, the addition of pertuzumab did not significantly influence the incidence of adverse events, and the use of biosimilars significantly reduced medical costs, with no significant difference in breast cancer recurrence rates. CONCLUSIONS: By analyzing two large and diverse datasets from multiple perspectives, we obtained reliable results that the trastuzumab originator and its biosimilars have similar safety profiles. The concurrent use of pertuzumab was also found to be safe. The use of biosimilars can lead to cost savings. These findings provide crucial insights for the evaluation and adoption of biosimilars in clinical practice.

DOI： 10.1007/s40259-024-00686-x

PubMed

researchmap

Long Short-Term Memory Algorithm for Personalized Tacrolimus Dosing: A Simple and Effective Time Series Forecasting Approach Post-Lung Transplantation

Haruki Choshi, Kentaroh Miyoshi, Maki Tanioka, Hayato Arai, Shin Tanaka, Kazuhiko Shien, Ken Suzawa, Mikio Okazaki, Seiichiro Sugimoto, Shinichi Toyooka

the Journal of Heart and Lung Transplantation in press 2024.10

明日からの乳癌診療に使える!最新の薬剤の使いどころ転移・再発乳癌に対するSG(サシツズマブゴビテカン)の使いどころ

突沖貴宏, 三又明日香, 中本翔伍, 岩谷陽子, 谷岡真樹, 岩谷胤生, 枝園忠彦

日本癌治療学会学術集会抄録集 62回 OSY11 - 5 2024.10

異時性遠隔再発を認めた非浸潤性乳管癌の2例

藤原由樹, 枝園忠彦, 三又明日香, 中本翔伍, 突沖貴宏, 高橋侑子, 谷岡真樹, 岩谷胤生

日本癌治療学会学術集会抄録集 62回 P73 - 2 2024.10

Primary angiosarcoma of the breast: a literature review. International journal

Yidan Zhu, Shogo Nakamoto, Takahiro Tsukioki, Yuko Takahashi, Yoko Iwatani, Tsuguo Iwatani, Xinfeng Zhang, Maki Tanioka, Tadahiko Shien

Chinese clinical oncology 2024.9

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND AND OBJECTIVE: Primary angiosarcoma of the breast (PBA) is an extremely rare and heterogeneous disease. PBA is difficult to diagnose and has a poor prognosis. In order to better understand the disease and provide evidence-based treatment for PBA patients, a review of the published literature in the English language was conducted. METHODS: A literature review in agreement with the PRISMA protocol was conducted. Medline and Cochrane databases were searched for English articles on PBA patients in September 2023 with a predetermined strategy. The articles were categorized and assessed based on hierarchical levels of scientific evidence. KEY CONTENT AND FINDINGS: A total of 255 articles were identified, among these 137 publications which included 1,888 patients met the criteria for inclusion in the final analysis. No prospective, randomized trials exclusive to PBA have been recognized. This article provides an overview of the most current and comprehensive evidence concerning the epidemiology, etiology, genomic features, clinical presentations, diagnosis, treatment, and prognosis of PBA. CONCLUSIONS: Despite the fact that current evidence is largely derived from retrospective studies, database analyses, and case reports, we utilized this information to tackle important clinical questions concerning optimal patient management practices for PBA. Complete surgical excision continues to be the mainstay treatment for PBA. However, the effectiveness of adjuvant therapies is still unclear. This narrative review highlights the urgent need for more rigorously designed research to enhance the management and treatment strategies for PBA.

DOI： 10.21037/cco-24-16

PubMed

researchmap

遺伝的および病理臨床的因子を用いた免疫関連有害事象の予測(Prediction of immune-related adverse events using genetic and clinicopathological factors)

井川由季子, 白石航也, 水野孝昭, 吉田達哉, 谷岡真樹, 濱野裕章, 高田健二, 市原英基, 大江裕一郎, 河野隆志, 河野隆志

日本癌学会総会記事 83回 E - 2024 2024.9

重篤な薬剤性心不全にて長期入院加療を要した2症例の検討

間森智加, 突沖貴宏, 三又明日香, 中本翔伍, 岩谷陽子, 高橋侑子, 谷岡真樹, 岩谷胤生, 枝園忠彦

日本乳癌学会総会プログラム抄録集 32回 480 - 480 2024.7

当院における乳腺葉状腫瘍の正診率と再発率の検討

中本翔伍, 突沖貴宏, 三又明日香, 高橋侑子, 岩谷陽子, 岩谷胤生, 谷岡真樹, 枝園忠彦

日本乳癌学会総会プログラム抄録集 32回 407 - 407 2024.7

術前薬物療法後病理学的完全奏効到達症例における早期遠隔再発症例の検討

高橋侑子, 三又明日香, 中本翔伍, 岩谷陽子, 突沖貴宏, 谷岡真樹, 岩谷胤生, 枝園忠彦

日本乳癌学会総会プログラム抄録集 32回 297 - 297 2024.7

多様な背景を持つ乳癌患者の意思決定支援 LGBTに対する乳癌診療の事例報告

枝園忠彦, 染田朋子, 露無祐子, 三又明日香, 間森智花, 中本翔吾, 岩谷陽子, 突沖貴宏, 高橋侑子, 岩谷胤生, 谷岡真樹

日本乳癌学会総会プログラム抄録集 32回 29 - 29 2024.7

BRCA病的バリアントを有する乳癌患者における術前化学療法に対する治療奏効率の検討

三又明日香, 高橋侑子, 中本翔伍, 突沖貴宏, 岩谷陽子, 谷岡真樹, 岩谷胤生, 枝園忠彦

日本乳癌学会総会プログラム抄録集 32回 289 - 289 2024.7

転移再発乳癌におけるがんゲノムプロファイリングの現状と問題点がん遺伝子パネル検査の前向き観察研究(REIWA study)の中間解析結果と乳癌ゲノム医療の問題点

多田寛, 増田紘子, 安立弥生, 岩谷胤生, 上本康明, 大谷陽子, 梶原友紀子, 北川大, 古川孝広, 相良安昭, 枝園忠彦, 田辺裕子, 谷岡真樹, 原文堅, 八十島宏行, 服部正也, 吉村健一, 岩田広治, 増田慎三

日本乳癌学会総会プログラム抄録集 32回 25 - 25 2024.7